Physician profile
Michael A Curtis
NPI 1821344912
$1,241.82
in general payments reported to CMS, 2019-2025
17 companies · $13.96 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $301 · 2021: $55.31 · 2022: $149 · 2023: $178 · 2024: $198 · 2025: $13.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $370.84 | 2019-2021 | |
| Oyster Point Pharma, INC. | $159.91 | 2022-2024 | Tyrvaya |
| Sight Sciences, INC. | $110.72 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $96.84 | 2022-2025 | Cequa |
| Shire North American Group INC | $84.15 | 2019 | |
| Alcon Vision LLC | $83.30 | 2023-2024 | Argos, Clareon, Centurion |
| Glaukos Corporation | $61.92 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $59.03 | 2022-2023 | Vyzulta, Lotemax Sm, Prolensa |
| Novartis Pharmaceuticals Corporation | $51.10 | 2019-2020 | |
| Abbvie INC. | $38.78 | 2024 | |
| Allergan, INC. | $37.07 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $17.54 | 2024 | Xdemvy |
| Rxsight INC | $16.00 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Tearlab Corp | $14.57 | 2024 | Scoutpro Osmolarity System |
| Eyevance Pharmaceuticals LLC | $13.89 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $13.88 | 2024 | Izervay |
| Evoke Pharma, INC. | $12.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.